Related Experiment Video
Updated: Jun 12, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Discovery of orally available spirodiketopiperazine-based CCR5 antagonists
Rena Nishizawa1, Toshihiko Nishiyama, Katsuya Hisaichi
1Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan. r.nishizawa@ono.co.jp
Abstract:
Using the previously reported novel spirodiketopiperazine scaffold, the design and synthesis of orally available CCR5 antagonists was undertaken. Compounds possessing a carboxylic acid function in the appropriate position showed improved oral exposure (AUC) relative to the initial chemical leads without reduction in the antagonist activity. The optimized compound 40 was found to show potent anti-HIV activity. Full details of structure-activity relationship (SAR) study are presented.
More Related Videos
Related Concept Videos
Antiprotozoal Agents
Drug Discovery: Overview
Antiviral Nucleoside Inhibitors
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Antipsychotic Drugs: Typical and Atypical Agents

